Percutaneous cholecystostomy in the treatment of acute calculous cholecystitis in elderly patients with COVID-19 and high comorbidity

Çağlayan Çakır, M.D.,1 Hamit Ahmet Kabuli, M.D.2

1Department of Radiology, Health Sciences University, Bakirköy Dr. Sadi Konuk Training and Research Hospital, İstanbul-Turkey
2Department of General Surgery, Health Sciences University, Bakirköy Dr. Sadi Konuk Training and Research Hospital, İstanbul-Turkey

ABSTRACT

BACKGROUND: The purpose of the study was to review the efficacy, safety, and outcomes of percutaneous cholecystostomy (PC) in elderly patients with acute calculous cholecystitis (ACC), high comorbidity, and COVID-19.

METHODS: The hospital registry data were examined of patients aged >65 years who were diagnosed with ACC and COVID-19 between March 2020 and June 2020 and who underwent PC treatment in the interventional radiology unit.

RESULTS: A total of 18 patients were diagnosed with ACC and COVID-19, then underwent PC. The patients comprised 14 (78%) males and 4 (22%) females with an average age of 73.4 years (range, 67–81 years). In 17 (94%) patients, symptoms associated with acute cholecystitis decreased within 48–72 h of the PC treatment and a clinical improvement was determined. The success rate of PC was 100% and no complications. In 3 (16.6%) patients followed up with intubation in intensive care after the procedure, mortality developed due to COVID-19-associated pneumonia and subsequent acute respiratory distress syndrome, and 15 (83.4%) patients were discharged with an elective cholecystectomy plan.

CONCLUSION: COVID-19 infection can be fatal especially in patients over 65 years of age due to additional comorbidities. PC treatment, which can be performed under local anesthesia as a minimally invasive procedure, is an alternative treatment option in this patient group. PC can also act as a bridge in transition to elective surgery in this process management.

Keywords: Acute calculous cholecystitis; COVID-19; high-risk patients; percutaneous cholecystostomy.

INTRODUCTION

A new coronavirus (2019) appeared in humans for the 1st time in the world in December 2019 and the disease caused by the virus infection was named COVID-19. The first cases were officially recorded in Turkey on March 11, 2020. COVID-19 is a highly contagious respiratory disease, with the main clinical symptoms of fever, dry cough, fatigue, muscle pain, and shortness of breath.[1]

Acute calculous cholecystitis (ACC) is one of the most common surgical emergencies encountered today, which presents with an acute abdomen picture. The coexistence of COVID-19 and ACC is very rare. Conservative methods, percutaneous cholecystostomy (PC), and surgery can be applied in the treatment of ACC. The main factors used to determine the treatment method are the patient’s age, comorbidities, and associated American Association of Anesthesiologists-Physical Condition Classification (ASA-PS) scores, acute cholecystitis (AC) severity index, and the time between the onset of the event and the application.

The main treatment method in patients suitable for surgery is early laparoscopic cholecystectomy. The recommended treatment options are determined according to the degree of AC severity in the Tokyo guidelines revised in 2018.[2] Early laparoscopic cholecystectomy in the patient group without low-risk comorbidities is the first option in treatment. Con-
surgical treatment and/or PC becomes more prominent with the laparoscopy experience of the center, and depending on the patient’s condition, should still be performed early in those at high risk and with increased comorbidities.\(^3\)

However, laparoscopic surgery and endoscopic procedures are not recommended in case of suspicion or diagnosis of COVID-19 disease.\(^4\)

For elderly patients in this series, it was thought that the risk of perioperative morbidity and mortality may increase due to low reserves and high comorbidities, in addition to the COVID-19 diagnosis or suspicion. The aim of this study was to review the effectiveness, reliability, and outcomes of PC in elderly patients (≥65 years) diagnosed with COVID-19.

**MATERIALS AND METHODS**

This study was approved by the ethics committee of Bakirkoy Dr Sadi Konuk Education and Research Hospital (approval number: 2020/443). A retrospective scan was made of the hospital registry system, and from a total of 24 patients applied with PC treatment for AC in the interventional radiology unit between March 2020 and June 2020, 18 patients were identified who were over 65 years old and were diagnosed with ACC and COVID-19.

The diagnosis of ACC was made based on the 2013 criteria of the Tokyo guideline.\(^5\) These criteria were as follows: (1) Murphy sign positivity or right upper quadrant pain as a sign of local inflammation, (2) fever with systemic signs of inflammation or elevated C-reactive protein or white blood cell count, and (3) characteristic radiological findings of ACC. The patients who met all three of these criteria were included in the study.

Patients diagnosed with cholelithiasis, pancreatitis, and gallbladder or biliary tract on first presentation were excluded from the study.

Cholelithiasis, gallbladder wall thickening (>5 mm) fluid, and positive sonographic Murphy findings were detected in the ultrasonography (US) examination of all the patients. In addition, the Tokyo 2018 severity grading for AC:

- **Mild (Grade I) AC:**
  Grade I can also be defined as AC in a healthy patient with no organ dysfunction and only mild inflammatory changes in the gallbladder, making cholecystectomy a safe and low-risk operative procedure.

- **Moderate (Grade II) AC:**
  “Moderate” AC is accompanied by anyone of the following conditions:
  1. Elevated WBC count (>18,000/mm\(^3\)).
  2. Palpable tender mass in the right upper abdominal quadrant
  3. Duration of complaints >72 h
  4. Marked local inflammation (biliary peritonitis, pericholecystic abscess, hepatic abscess, gangrenous cholecystitis, emphysematous cholecystitis)
  a: Laparoscopic surgery in AC should be performed within 96 h after the onset (level 2b-4)

- **Severe (Grade III) AC:**
  “Severe” acute cholecystitis is accompanied by dysfunctions in any of the following organs/systems
  1. Cardiovascular dysfunction (hypotension requiring treatment with dopamine ≥5 µg/kg/min, or any dose of norepinephrine)
  2. Neurological dysfunction (decreased level of consciousness)
  3. Respiratory dysfunction (PaO\(_2\)/FiO\(_2\) ratio <300)
  4. Renal dysfunction: (oliguria, creatinine >2.0 mg/dl)
  5. Hepatic dysfunction (PT-INR >1.5)
  6. Hematological dysfunction (platelet count <100,000 mm\(^3\)).

**Table 1.** The Tokyo 2018 severity grading for AC

| Grade | Description |
|-------|-------------|
| I     | Mild AC, healthy patient with mild inflammation |
| II    | Moderate AC, increased WBC count, abdominal pain, local inflammation |
| III   | Severe AC, cardiovascular, neurological, respiratory, renal, and hepatic dysfunctions |

**Figure 1.** Management of acute cholecystitis according to the Tokyo 2018 guidelines. GB: Gallbladder; LC: Laparoscopic cholecystectomy.
IV contrast abdominal computed tomography (CT) tests were performed on all patients to evaluate possible complications (gallbladder perforation, acute pancreatitis, malignancy, etc.).

The Tokyo 2018 Guidelines classify the severity of AC into three grades in Table 1 and flowcharts for the management of AC are shown in Figure 1. Antibiotic treatment was started after the PC procedure for ACC. According to the hemogram and hemorrhage parameters, fresh frozen plasma was administered to patients with a high international normalized ratio value, and for patients with low platelet values, PC was performed after normal values were obtained.

For the PC procedure applied in the interventional radiology unit, the patients were accepted as a high-risk group in terms of COVID-19, so double gloves, protective overshoes, and disposable surgical gowns were worn in addition to N95 mask, surgical cap, and face shield.

All procedures were performed under local anesthesia, with the Seldinger method, using a US-transhepatic or transperitoneal approach to place a lock pigtail 10 Fr catheter into the gallbladder. The first sample was sent to the microbiology department. After the PC procedure, the patients were followed up with daily drainage and clinical observation.

**RESULTS**

A total of 18 patients, diagnosed with ACC with COVID-19, underwent PC. The patients comprised 14 (78%) males and 4 (22%) females with an average age of 73.4 years (range, 67–81 years). The technical success was 100% and all of the patients were treated using the Seldinger technique under US guidance. No procedural mortality was observed.

Ten (55.6%) patients were evaluated as ASA III, 6 (33.3%) as ASA IV, and 2 (11.1%) as ASA V due to existing comorbidities. The comorbid diseases and clinical follow-up processes of the patients are summarized in Table 2. According to Tokyo 2018 guidelines, 3 (16.7%) patients were evaluated as mild, 9 (50%) patients as moderate, and 6 (33.3%) patients as severe AC.

The patients did not have any respiratory symptoms at the time of admission. At the stage of diagnosis, thorax

| Patient No./Sex/Age (years) | ASA-PC Score | Comorbidity | COVID-19 (RTPCR Test) | Pre-interventional CRP (mg/L) and Leucocytes (10^3/µl) | Length of stay (days) | Outcome |
|-----------------------------|--------------|-------------|----------------------|-------------------------------------------------------|-----------------------|---------|
| 1/M/75                      | 4 + + +      | +           | +                    | 130/21                                               | 24                    | Death   |
| 2/M/67                      | 3 +          | +           | +                    | 126/11                                               | 4                     | Discharged |
| 3/M/73                      | 4 +          | +           | +                    | 38/18                                                | 32                    | Discharged |
| 4/M/81                      | 5 + + + + +  | +           | +                    | 231/15                                               | 3                     | Death   |
| 5/F/81                      | 3 + + +      | +           | +                    | 52/15                                                | 5                     | Discharged |
| 6/M/67                      | 3 + + +      | +           | +                    | 42/11                                                | 4                     | Discharged |
| 7/M/70                      | 3 + + +      | +           | +                    | 28/11                                                | 21                    | Discharged |
| 8/F/79                      | 3 + + +      | +           | +                    | 14/18                                                | 10                    | Discharged |
| 9/M/68                      | 4 +          | +           | +                    | 14/11                                                | 3                     | Discharged |
| 10/M/74                     | 4 +          | +           | +                    | 16/11                                                | 28                    | Discharged |
| 11/M/68                     | 3 + + +      | +           | +                    | 23/14                                                | 3                     | Discharged |
| 12/M/70                     | 4 + + +      | +           | +                    | 41/13                                                | 18                    | Discharged |
| 13/M/81                     | 5 + + +      | +           | +                    | 307/19                                               | 13                    | Death   |
| 14/M/81                     | 3 + + +      | +           | +                    | 42/15                                                | 5                     | Discharged |
| 15/M/67                     | 3 +          | +           | +                    | 185/15                                               | 4                     | Discharged |
| 16/M/73                     | 3 + + +      | +           | +                    | 50/11                                                | 6                     | Discharged |
| 17/F/79                     | 3 + + +      | +           | +                    | 33/18                                                | 10                    | Discharged |
| 18/M/68                     | 4 +          | +           | +                    | 22/12                                                | 3                     | Discharged |

ASA-PC: American Association of Anesthesiologists-Physical Condition Classification; RTPCR: Reverse transcriptase-polymerase chain reaction; COPD: Chronic obstructive pulmonary disease; CRP: (C-reactive protein) standard value <5 mg/L and Leucocytes standard value 4–11 (10^3/µl); M: Male; F: Female.
CT was applied because of the risk factors of age >65 years and comorbidities (diabetes, hypertension, congestive heart failure, chronic kidney failure, and chronic obstructive pulmonary disease [COPD]). The findings were found to be significant in terms of COVID-19, and from nasal and pharyngeal swabs, 9/18 patients were diagnosed with COVID-19 using the timed reverse transcriptase-polymerase chain reaction (RTPCR) test. The RTPCR test was negative in nine patients and although there were no respiratory symptoms, medical treatment was started with the consultation of the infectious diseases specialist due to COVID-19-positive radiological findings and the presence of comorbidities.

Symptoms associated with AC decreased within 48–72 h and clinically improved in 17 (94%) patients. There were no major complications associated with the PC procedure.

A total of 26 bacterial strains were isolated in bile samples obtained from 18 patients. Pseudomonas aeruginosa was the most common bacterium growing in the bile sample cultures of the patients, and one-third of the samples were polymicrobial. COVID-19 was not determined in any of the bile sample cultures.

Follow-up in the intensive care unit with intubation was required by 3 (16.6%) patients, and mortality developed in these 3 patients due to COVID-19-associated organizing pneumonia and acute respiratory distress syndrome (ARDS). While under clinical follow-up, catheter dislocation occurred in two patients, and after antibiotic prophylaxis applied under local anesthesia under standard sterile conditions, the catheters were reinstalled under fluoroscopy guidance. No additional interventional radiological procedure was applied to any patient. The average follow-up period for all the patients was 4 months (between 2 and 5 months). Elective cholecystectomy was performed in 5 (27.7%) patients.

DISCUSSION

The newly discovered outbreak of SARS-CoV-2 infection was named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 was declared as a pandemic by the WHO in March 2020 and spread rapidly to many countries around the world. The most common symptoms are fever, cough, shortness of breath, and organizing pneumonia characterized by bilateral infiltrates on lung imaging in COVID-19 cases. However, there is no specific clinical feature that allows COVID-19 to be differentiated from other viral respiratory infections. In some studies from China, smell and taste disorders (anosmia and dysgeusia) have also been described as other common symptoms in patients with COVID-19. Although studies with similar results have been conducted, it is still controversial whether these symptoms are a distinctive feature of COVID-19 in Italy. The prevalence of gastrointestinal symptoms has been reported as diarrhea in 18% and nausea-vomiting in 13% in various meta-analyses and acute abdomen is seen very rarely.

In the current series, patients were diagnosed with ACC as a result of the emergency acute abdomen picture, which was the main reason for presentation. The association of ACC and COVID-19 is rarely seen, and care should be taken in terms of treatment selection and planning for this patient group.

Respiratory symptoms that may be associated with COVID-19 were not detected in this patient group, but due to the COVID-19 outbreak, which has been declared as a pandemic worldwide, especially in patients over 65 years of age and with additional comorbidity, thorax CT and abdominal CT examination can be performed to evaluate possible complications (gallbladder perforation, acute pancreatitis, malignancy etc.).

Although radiology organizations and associations are against the use of thorax CT for the purpose of screening in the diagnosis of COVID-19, radiological imaging methods are widely used at the diagnosis stage and in the evaluation of complications for various reasons.

RTPCR test is the gold standard in the diagnosis of COVID-19. However, besides the limitations on the availability of this test, variables such as adequacy of sample quantity, type, transportation, and the time of the disease affect the sensitivity in clinical practice. In the current study, only half of the patients were diagnosed using the RTPCR test. The fact that the test sensitivity is not high enough and the difficulties in availability of the test are the most important reasons to increase the use of direct radiography and CT in diagnosis. Direct radiography is not sensitive and has a low diagnostic value in patients who have no significant respiratory complaints in the early period as in the current series.

It has been specified in varying rates and it has been stated that it can be performed at low-dose or standard dose parameters at the stage of diagnosis. In COVID-19 patients, the ground-glass opacity appearance in the form of a nodule or mass located in the peripheral and posterior position, usually in the organizing pneumonia style, is typical. In addition, consolidations, linear, curvilinear, and perilobular opacities may also be present (Case 1, Fig. 2).

In cases of suspected COVID-19 requiring urgent surgery, there is no need to wait for the definitive diagnosis of COVID-19. These patients should be included in the surgical procedure in the same way as those diagnosed with COVID-19. In the current series, the PC procedure was performed considering COVID-19.
Despite the increasing number of cases of COVID-19 worldwide, the combination of COVID-19 and ACC is very rare. In the treatment of ACC, laparoscopic cholecystectomy is the currently accepted most appropriate treatment option. However, laparoscopic surgery is performed by creating an artificial pneumoperitoneum. The ultrasonic or electrical equipment used in the process produces large amounts of surgical smoke, and the surgical team is at risk of aerosol exposure. Therefore, laparoscopic surgery and endoscopic procedures are generally not recommended in patients with diagnosed or suspected COVID-19.

The majority of ACC cases are seen in elderly patients and are more severe than in younger patients. Patient age of over 65 years and the presence of comorbidities (cardiovascular disease, hypertension, diabetes, chronic respiratory disease, and immune deficiency) have been identified as important risk factors for the progression of COVID-19 disease. In a study in Wuhan, China, ARDS developed in 41% of patients with COVID-19 who were hospitalized, and age >65 years, diabetes mellitus, and hypertension were found to be factors associated with ARDS. In the current series, two of the three patients who died were diagnosed with diabetes mellitus and hypertension, as well as congestive heart failure and COPD. Due to these defined comorbidities, non-surgical treatments should be applied to patients over 65 years of age with ACC and COVID-19.

There has been found to be a significant difference in morbidity and mortality between elective surgery and emergency surgery for ACC. In a prospective study which compared patients undergoing elective and emergency cholecystectomy, it was reported that morbidity rates increased from 28% to 66% and mortality rates from 1% to 19% in emergency surgery for ACC. Adding COVID-19 disease to these cases will undoubtedly increase the morbidity and mortality rates.

In addition, COVID-19 pneumonia is particularly high in the peri- and post-operative periods, and as it has a high mortality rate, any surgical treatment should be considered very carefully. The current common opinion for elective cases is to postpone the surgery as much as possible and to plan for a more appropriate time.

In the case of perforation, abscess, and sepsis together with ACC, PC should be kept in mind as an alternative treatment method. At present, local symptoms and inflammatory response can be controlled with PC. Clinical success is generally defined as a decrease in fever, leukocyte count, and pain in 72 h.

In the current patient group, three patients died due to COVID-19 disease. Mortality associated with PC has generally been reported to be below 1% and was not seen in this series. In a large-scale review by Winbladh et al., it was stated that up to 40% of patients undergoing PC undergo elective cholecystectomy. In the current series, medical treatments for COVID-19 were completed and elective cholecystectomy was performed in 5 (27.7%) patients. The below-average rate of elective cholecystectomy can be attributed to the study group only including elderly COVID-19 patients with calculous cholecystitis.

Catheter dislocation is one of the most frequently reported complications in the PC procedure, although it is below 10% in general. Catheter dislocation occurred in two patients in the current series and the catheters were successfully replaced.

Other complications such as hemorrhage, biliary peritonitis, pneumothorax, secondary infection, and sepsis have also been reported at low rates but none of these were observed in the current series.

In patients with ACC, high comorbidity, and COVID-19 diagnosed during the pandemic, PC may be a life-saving treatment procedure in emergencies, as well as an intermediate line treatment option until elective surgery after medical treatment. In addition, laparoscopic cholecystectomy experience has shown a general tendency to avoid early cholecystectomy.
in centers with low experience, and surgery should be avoided when COVID-19 disease and additional comorbidities are present in patients aged over 65 years.[39]

Conclusion
In the light of these data, PC can be applied as an alternative and first-line treatment option for high-risk elderly patients with COVID-19. In this process management, PC can also act as a bridge in transition to elective surgery.

Ethics Committee Approval: This study was approved by the ethics committee of Bakirköy Dr Sadi Konuk Education and Research Hospital (approval number: 2020/443).

Peer-review: Internally peer-reviewed.

Authorship Contributions: Concept: Ç.Ç.; Design: Ç.Ç.; Supervision: Ç.Ç.; Resource: Ç.Ç.; Materials: Ç.Ç.; Data: Ç.Ç.; Analysis: Ç.Ç.; Literature search: Ç.Ç.; Writing: Ç.Ç.; Critical revision: Ç.Ç., H.A.K.

Conflict of Interest: None declared.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES
1. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): Disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents 2020;55:105946. [CrossRef]
2. Kiriyma S, Kozaka K, Tkadka T, Straszberg SM, Pitt HA, Gabata T, et al. Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci 2018;25:17–30. [CrossRef]
3. Okamoto K, Suzuki K, Tkadka T, Straszberg SM, Asbun HJ, Endo I, et al. Tokyo Guidelines 2018: Flowchart for the management of acute cholecystitis. J Hepatobiliary Pancreat Sci 2018;25:55–72. [CrossRef]
4. Karaca AS, Öztmen MM, Uçar AD, A. Yaşlı Ç, Demirer S. COVID-19’la Hastalarda genel cerrahi ameliyat uygulamaları. Türk J Surg 2020;36:VI–X. [CrossRef]
5. Yokoe M, Tkadka T, Hwang TL, Endo I, Akazawa K, Miura F, et al. Validation of TG13 severity grading in acute cholecystitis: Japan-Taiwan collaborative study for acute cholecystitis. J Hepatobiliary Pancreat Sci 2017;24:338–45. [CrossRef]
6. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr 2020;63:119–24. [CrossRef]
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9. [CrossRef]
8. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323:1775–6. [CrossRef]
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239–42. [CrossRef]
10. Kooraki S, Hosseiny M, Myers L, Gholamrezaeezhaad A. Coronavirus (COVID-19) outbreak: What the department of radiology should know. J Am Coll Radiol 2020;17:447–51. [CrossRef]
11. Wong HY, Lam HY, Fong AH, Leung ST, Chin TW, Lo CS, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology 2020;296:E72–8. [CrossRef]
12. Society of Thoracic Radiology/American Society of Emergency Radiology COVID-19 Position Statement; 2020. Available from: https://www.acr.org/advocacyand-economics/acr-ositionstatements/recommendations-forchest-radiography-and-ct-forsuspected-covid-19-infection. [CrossRef]
13. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection; 2020. Available from: https://www.acr.org/advocacyand-economics/acr-ositionstatements/recommendations-forchest-radiography-and-ct-forsuspected-covid-19-infection. [CrossRef]
14. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020;296:E32–40. [CrossRef]
15. The ACPGBI. Urgent Intercollegiate General Surgery Guidance on COVID-19. Ireland: The Association of Coloproctology of Great Britain and Ireland; 2020.
16. Loozen CS, van Santvoort HC, van Duijvendijk P, Besselink MG, Gouma DJ, Nieuwenhuijzen GA, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high risk patients (CHOCOLATE): Multicentre randomised clinical trial. BMJ 2018;363:k3965. [CrossRef]
17. American College of Surgeons. COVID-19 and Surgery. COVID-19: Elective Case Triage Guidelines for Surgical Care Online March 24, 2020.
18. Bergman S, Sourial N, Vedel I, Hanna WC, Fraser SA, Newman D, et al. Gallstone disease in the elderly: Are elderly patients managed differently? Surg Endosc 2011;25:55–61. [CrossRef]
19. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934–43. [CrossRef]
20. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020;368:m1091. [CrossRef]
21. Donati A, Ruzzi M, Adriario E, Pelaia P, Coluzzi F, Gabbanelli V, et al. A new and feasible model for predicting operative risk. Br J Anaesth 2004;93:393–9. [CrossRef]
22. Houghton PW, Jenkinson LR, Donaldson LA. Cholecystectomy in the elderly: A prospective study. Br J Surg 1985;72:220–2. [CrossRef]
23. Griniatsos J, Petrou A, Pappas P, Revenas K, Karavokyros I, Michail OP, et al. Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci 2018;25:55–72. [CrossRef]
24. Winbladh A, Gullstrand P, Svanvik J, Sandström P. Systematic review of cholecystectomy as a treatment option in acute cholecystitis. HPB (Oxford) 2009;11:183–93. [CrossRef]
25. Tieng LJ, Tsai CC, Mo LR, Lin RC, Kuo CY, Jiang KK, et al. Palliative percutaneous transhepatic gallbladder drainage of gallbladder empyema before laparoscopic cholecystectomy. Hepatogastroenterology 2000;47:932–6.
26. Ito K, Fujita N, Noda Y, Kobayashi G, Kimura K, Sugawara T, et al. Percutaneous cholecystostomy versus gallbladder aspiration for acute cholecystitis: A prospective randomized controlled trial. AJR Am J Roentgenol 2004;183:193–6. [CrossRef]
Çakır et al. PC in the treatment of ACC in elderly patients with COVID-19 and high comorbidity

ORİJİNAL ÇALIŞMA - ÖZET

Yeni koronavirüs (COVID-19) hastalığı olan yaşlı ve yüksek komorbiditeli hastalarda akut taşlı kolesistit tedavisinde perkütan kolesistostomi

Dr. Çağlayan Çakır,¹ Dr. Hamit Ahmet Kabuli²

¹ Sağlık Bilimleri Üniversitesi Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi Radyoloji Anabilim Dalı, İstanbul
² Sağlık Bilimleri Üniversitesi Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi Genel Cerrahi Anabilim Dalı, İstanbul

AMAÇ: Akut taşlı kolesistit (ATK) ve COVID-19 tanıları yüksek komorbiditesi olan yaşlı hastalarda perkütan kolesistostominin (PK) etkinliğini, güvenilirliğini ve sonuçlarını gözden geçirmeyi amaçladık.

GEREÇ VE YÖNTEM: Mart 2020–Haziran 2020 tarihleri arasında ATK ve COVID-19 tanıları olan ve girişimsel radyoloji ünitesinde PK tedavi işlemi yapılan 65 yaş üstü hastaların verileri hastane kayıt sistemi taraftarak incelendi.

BULGULAR: COVID-19 ile birlikte ATK tanıları alan toplam 18 hastaya PK işlemi yapıldı. Hastaların 14’ü (%78) erkek ve dörtü (%22) kadın; ortalaması yaş 73.4 (dalgımlı, 67–81 yıl). Hastaların 17’inde (%94) 48–72 saat içerisinde akut kolesistit ile ilişkili semptomlar gerilemiş ve klinik olarak düzelmiştir. Perkütan kolesistostomi uygulamasının başarılı oranı %100 olup herhangi bir komplikasyon gelişmemiştir. Uç (%16.6) hasta işlem sonrası yoğun bakımda entübe olarak izlenmekte iken COVID-19 ilişkili organize pnömoni ve sonrasında gelişen akut respiratuar distress sendromu (ARDS) nedeniyle hayatını kaybetti. Hastaların 15’i (%83.4) elektif kolesistektomi planı yapılarak taburcu edildi.

TARTIŞMA: Dünya genelinde şiddeti giderek artan COVID-19 salgını özellikle 65 yaş üstü hastalarda ek komorbidit hastalıklardan dolayı ölümü olabilmektedir. Bu hastalarda ATK tedavisinde PK, minimal invaziv ve lokal anestezi altında yapılabilir alternatif tedavi seçeneğidir. Ayrıca bu süreç yönetimeki PK elektif cerrahiye geçişte köprü görevi görebilir.

Anahtar sözcükler: Akut taşlı kolesistit; COVID-19; perkütan kolesistostomi; yüksek riskli hastalar.

Ulus Travma Acil Cerrahi Derg 2021;27(3):296-302  doi: 10.14744/tjtes.2020.23255